Hormone Optimization for Longevity: Testosterone, Estrogen, Thyroid, and Beyond

The Hormonal Ageing Problem#

Hormones are the body's long-distance signalling system — chemical messengers that regulate metabolism, muscle mass, bone density, cognition, mood, immune function, and virtually every aspect of physiology. Their decline with age is not incidental — it is central to the ageing process.

Key hormonal changes with age:

• Testosterone: Declines approximately 1–2% per year in men from age 30; often not measured in women
• Estrogen: Drops precipitously at menopause (typically 45–55); gradual decline in men with age
• Growth hormone: Declines 14% per decade after age 30; associated with declining IGF-1
• DHEA: Declines 80–90% between age 20 and 80 — the steepest age-related hormonal decline of any compound
• Thyroid: Often not declining per se, but conversion from T4 to active T3 becomes impaired with age and stress
• Melatonin: Declines significantly from age 40–50, contributing to sleep disruption

The mainstream medical approach is to treat hormonal levels as acceptable as long as they are "within normal range." The problem: normal ranges are calibrated against the general population, which is increasingly metabolically unhealthy and aging. Being at the 10th percentile of testosterone for your age is "normal" but produces significantly different health outcomes than being at the 80th percentile.

Longevity medicine takes a different view: optimise hormones toward youthful physiological levels, not merely above the floor of pathological deficiency.

---

Testosterone: The Most Important Hormone for Both Sexes#

Men#

Testosterone regulates:

• Muscle mass and strength (primary anabolic hormone)
• Bone density (hypogonadal men develop osteoporosis)
• Libido and erectile function
• Cognitive function — verbal memory, spatial processing
• Mood and motivation — low T is strongly associated with depression
• Metabolic health — testosterone improves insulin sensitivity
• Red blood cell production
• Cardiovascular risk factors

The decline: Total testosterone declines approximately 1–2% per year from age 30. By age 50, the average man has testosterone levels 30–40% below his youthful peak. By 70, this exceeds 50% decline.

What to measure:

• Total testosterone
• Free testosterone (the biologically active fraction — more important than total in older men with elevated SHBG)
• SHBG (sex hormone binding globulin — increases with age, binding more testosterone)
• LH and FSH (distinguish primary vs secondary hypogonadism)
• Estradiol (testosterone aromatises to estrogen — both too high and too low estradiol cause problems)
• Hematocrit (TRT raises red blood cell count — monitor)

Optimisation without TRT (first line):

• Resistance training — the most potent natural testosterone stimulus available
• Sleep optimisation — most testosterone is released during deep sleep; short sleep acutely reduces testosterone 10–15%
• Body fat reduction — aromatase in fat tissue converts testosterone to estrogen
• Zinc supplementation (if deficient) — zinc is rate-limiting for testosterone synthesis
• Vitamin D3 — associated with testosterone in multiple studies; correct deficiency first
• Stress reduction — chronic cortisol suppresses testosterone synthesis
• Reduce alcohol — even moderate alcohol significantly reduces testosterone

TRT (Testosterone Replacement Therapy): For men with confirmed hypogonadism (total testosterone consistently below 300 ng/dL, or free testosterone below range) who have not responded to lifestyle optimisation, TRT is a well-evidenced intervention.

TRT evidence for longevity:

• The TRAVERSE trial (2023, NEJM): Testosterone therapy in men with hypogonadism and cardiovascular risk did not increase cardiovascular events (allaying a long-standing concern)
• Multiple studies show TRT reduces all-cause mortality in hypogonadal men vs untreated controls
• Improves body composition, bone density, insulin sensitivity, and cognitive function

TRT options:

• Testosterone cypionate or enanthate (weekly injection): Most cost-effective; most studied
• Testosterone gel (daily): Convenient; risk of transference to partners
• Pellet implants (quarterly): Consistent levels; requires insertion procedure
• Oral testosterone undecanoate (Jatenzo, Kyzatrex): FDA-approved for oral TRT; food-dependent absorption

Critical consideration: TRT suppresses endogenous testosterone production and reduces fertility by suppressing LH/FSH. Men wanting to preserve fertility should use clomiphene or HCG rather than exogenous testosterone.

Women#

Testosterone is not a "male hormone" — women produce testosterone in the ovaries and adrenal glands, and it plays critical roles in female physiology that are systematically undertested and undertreated.

In women, testosterone affects:

• Libido (the most clinically obvious effect of low T in women)
• Muscle mass and strength
• Bone density
• Cognitive function and mood
• Energy levels

Women's testosterone declines significantly through the 30s and 40s — often decades before menopause. Low testosterone in women is common and frequently undiagnosed because it is rarely tested.

Testosterone in peri/postmenopause: Many women experience significant quality-of-life improvement from low-dose testosterone supplementation alongside HRT. The evidence for this is substantial enough that the British Menopause Society and several other professional bodies now formally support testosterone supplementation in appropriate women.

---

Estrogen and Progesterone: The Menopause Discussion#

The Women's Health Initiative (WHI) study in 2002 produced widespread fear of hormone replacement therapy (HRT) after reporting increased breast cancer and cardiovascular risks. This led to a generation of women being undertreated for menopausal symptoms.

The WHI data has since been substantially reinterpreted:

• The study used conjugated equine estrogen (from horse urine) and medroxyprogesterone acetate (a synthetic progestogen) — not bioidentical hormones
• The study enrolled women with an average age of 63 — 10+ years post-menopause. The risks did not apply to recently menopausal women
• Bioidentical estradiol (the body's own estrogen, delivered transdermally) and micronised progesterone have a substantially better risk profile

Current evidence on bioidentical HRT:

• Transdermal estradiol does NOT increase VTE (venous thromboembolism) risk (unlike oral estrogen)
• Micronised progesterone does NOT increase breast cancer risk in the same way as synthetic progestogens
• HRT initiated within 10 years of menopause significantly reduces cardiovascular disease risk ("timing hypothesis" or "window of opportunity")
• HRT reduces osteoporosis risk, dementia risk (estrogen is neuroprotective), and all-cause mortality in appropriately selected women

Peter Attia, Louann Brizendine, and the Menopause Society now strongly support bioidentical HRT initiated near the time of menopause for most women without contraindications.

Contraindications to HRT:

• Personal history of estrogen-receptor-positive breast cancer
• Active or history of blood clots (VTE) — transdermal route largely mitigates this
• Active liver disease
• Unexplained vaginal bleeding

---

Thyroid: The Overlooked Driver#

The thyroid produces two hormones:

• T4 (thyroxine): The storage form; produced by the thyroid
• T3 (triiodothyronine): The active form; produced by peripheral conversion of T4

Standard thyroid testing (TSH alone, or TSH + T4) misses the most common functional thyroid problem: adequate T4 production with impaired T4→T3 conversion. This conversion occurs primarily in the liver and gut and is impaired by:

• Chronic stress (cortisol inhibits deiodinase enzymes)
• Selenium deficiency (deiodinase enzymes are selenium-dependent)
• Insulin resistance
• Inflammatory states
• Caloric restriction

Symptoms of low free T3 (with normal TSH and T4):

• Fatigue, particularly morning grogginess
• Cold intolerance
• Brain fog
• Hair thinning
• Constipation
• Low mood

What to test:

• TSH (standard; low sensitivity for functional problems)
• Free T4 (most of what the thyroid produces)
• Free T3 (the active hormone — most important for symptoms)
• Reverse T3 (inactive isomer that competes with free T3; elevated in chronic stress and illness)
• Thyroid antibodies (TPO, thyroglobulin — screen for autoimmune thyroiditis)

Optimisation:

• Selenium 200mcg/day (supports deiodinase function)
• Zinc 15–30mg/day (thyroid hormone synthesis)
• Iodine (usually adequate in Western diets; deficiency in plant-based diets)
• Address chronic stress (the primary suppressor of T4→T3 conversion)
• If low free T3 persists: discuss liothyronine (T3) supplementation with a physician — standard treatment is T4 only (levothyroxine), but some patients benefit significantly from T3 or combination T4/T3 therapy

---

DHEA: The Forgotten Longevity Hormone#

DHEA (dehydroepiandrosterone) is the most abundant circulating steroid hormone in the body. It serves as the precursor for sex hormone synthesis (testosterone and estrogen are made from DHEA) and has independent effects on immune function, cognitive health, and stress resilience.

The decline: DHEA declines more steeply with age than any other measured hormone — from peak levels in the mid-20s to approximately 10–20% of peak by age 80. This 80–90% decline is one of the most dramatic age-related biological changes measured.

Centenarian studies consistently show that long-lived individuals maintain higher DHEA levels than age-matched controls — suggesting either that high DHEA contributes to longevity or that it is a biomarker of slower biological ageing.

Evidence for supplementation:

• Several RCTs show DHEA supplementation improves bone density in older women
• Cognitive benefits in older adults with low DHEA (memory and processing speed)
• Immune function enhancement
• Improved wellbeing and reduced depression in older adults with documented DHEA deficiency

Protocol:

• Test DHEA-S (the sulfated storage form) before supplementing
• Typical longevity dose: 25–50mg/day (men), 10–25mg/day (women)
• Use DHEA-S levels as a guide — target the mid-range for your youthful levels
• Pregnenolone (25–50mg/day) — the upstream precursor to DHEA — is an alternative some longevity physicians prefer for its broader precursor role

---

Growth Hormone and IGF-1#

Growth hormone secretion declines 14% per decade after age 30. This decline is associated with:

• Reduced muscle mass and increased fat mass
• Reduced bone density
• Impaired sleep (GH secretion peaks during deep sleep)
• Fatigue and reduced recovery

Optimising GH naturally:

• Resistance training — the most potent GH stimulus
• Deep sleep — most GH is released during slow-wave sleep; optimising sleep architecture optimises GH
• Intermittent fasting — fasting significantly increases GH secretion (the longevity mechanism may partly be GH-mediated)
• Two sauna sessions of 15 minutes with 30-minute cooling interval produces a 16-fold GH increase — the largest non-pharmacological GH stimulus known

Pharmacological GH augmentation:

• CJC-1295 + Ipamorelin (growth hormone releasing peptides) — discussed in our peptides guide
• Sermorelin (GHRH analogue) — compounded, physician-supervised
• Exogenous recombinant HGH — controlled substance with significant misuse history and genuine risk of IGF-1 over-elevation

Caution: IGF-1 elevation is a double-edged sword. Low IGF-1 is associated with Laron syndrome (extreme longevity but short stature). High IGF-1 is associated with cancer risk. The goal is not maximum GH/IGF-1 — it is restoration toward youthful physiological levels, not supraphysiological excess.

---

The Hormonal Optimization Assessment Protocol#

Baseline blood panel (annual, ideally in the morning fasting):

• Total and free testosterone
• SHBG
• Estradiol (E2)
• DHEA-S
• IGF-1
• TSH, free T3, free T4, reverse T3
• Thyroid antibodies (TPO, anti-TG)
• Cortisol (ideally 4-point salivary cortisol curve for full picture)
• LH, FSH (in men for hypogonadism evaluation; in women for menopause staging)

Finding the right physician: Standard GPs and endocrinologists are trained to treat pathological hormone deficiency (hypogonadism, hypothyroidism, Addison's). They are less trained in the optimisation approach — treating hormones toward youthful ranges in people who are technically "within normal."

Look for physicians with training in:

• Longevity medicine (A4M fellowship, IFM)
• Men's health / testosterone therapy
• Menopause medicine (British Menopause Society members in UK; NAMS in US)
• Functional medicine

Telehealth options: Defy Medical, Marek Health (US), Numan, Manual (UK) — provide online consultations with physicians experienced in hormone optimisation.

---

Non-Pharmaceutical Hormone Support Stack#

Before pursuing TRT, HRT, or thyroid medication, these interventions address the most common modifiable drivers of hormonal decline:

For testosterone (men and women):

• Resistance training 3–4x/week
• 7–9 hours sleep (non-negotiable)
• Zinc 15–30mg/day
• Vitamin D3 3,000–5,000 IU/day
• Ashwagandha 600mg/day (multiple RCTs show 15–20% testosterone increase)
• Reduce alcohol, stress, and excess body fat

For thyroid:

• Selenium 200mcg/day
• Zinc 15–30mg/day
• Iodine (from food; kelp/seaweed or iodised salt)
• Stress management (cortisol inhibits T3 conversion)

For DHEA:

• Regular exercise (acute DHEA increases with training)
• Adequate sleep
• Stress reduction (DHEA and cortisol are inversely related)
• Supplement if bloodwork confirms decline: 25–50mg/day